Published in Nature on May 21, 2007
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
Translating insights from the cancer genome into clinical practice. Nature (2008) 4.37
Telomeres and telomerase in cancer. Carcinogenesis (2009) 4.28
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
Making sense of cancer genomic data. Genes Dev (2011) 3.01
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest (2008) 2.68
Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis. EMBO J (2007) 2.61
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol (2010) 2.58
Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol (2013) 2.56
Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer (2008) 2.54
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci U S A (2008) 2.48
Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature (2008) 2.47
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med (2011) 2.40
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet (2011) 2.32
A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med (2008) 2.31
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood (2009) 2.29
Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med (2008) 2.19
Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev (2008) 2.12
Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med (2008) 2.06
A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet (2011) 1.99
Cell competition is a tumour suppressor mechanism in the thymus. Nature (2014) 1.97
Exonuclease-1 deletion impairs DNA damage signaling and prolongs lifespan of telomere-dysfunctional mice. Cell (2007) 1.96
The quest for the 1p36 tumor suppressor. Cancer Res (2008) 1.95
The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med (2010) 1.93
Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer (2010) 1.93
Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood (2010) 1.92
Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell (2012) 1.91
The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle (2008) 1.83
Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer (2010) 1.80
Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med (2013) 1.71
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol (2013) 1.68
The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia (2010) 1.56
Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin Cancer Res (2013) 1.53
Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell (2014) 1.51
Roles of F-box proteins in cancer. Nat Rev Cancer (2014) 1.51
Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer (2010) 1.51
Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1. J Exp Med (2008) 1.49
Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol Cell (2012) 1.48
Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica (2009) 1.48
Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia. J Exp Med (2012) 1.44
The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation. Oncogene (2010) 1.41
Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood (2010) 1.40
STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes Dev (2012) 1.38
Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med (2007) 1.37
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest (2010) 1.35
Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Res (2009) 1.34
Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res (2013) 1.33
Notch signaling: switching an oncogene to a tumor suppressor. Blood (2014) 1.32
From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets. Nat Rev Cancer (2012) 1.32
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med (2011) 1.31
Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate (2009) 1.30
Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7. Cell Host Microbe (2013) 1.27
MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem (2010) 1.26
Regulation of cell differentiation by the DNA damage response. Trends Cell Biol (2011) 1.25
HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets (2009) 1.25
SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov (2014) 1.25
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A (2010) 1.25
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood (2014) 1.23
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood (2009) 1.23
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol (2009) 1.22
Chromosomes and cancer cells. Chromosome Res (2011) 1.21
An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep (2013) 1.21
Genetically engineered mouse models in cancer research. Adv Cancer Res (2010) 1.18
The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica (2012) 1.18
Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver. J Clin Invest (2010) 1.17
Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. J Clin Invest (2010) 1.17
Evading apoptosis in cancer. Trends Cell Biol (2013) 1.17
Mcl-1 ubiquitination and destruction. Oncotarget (2011) 1.17
The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med (2013) 1.14
Insights from mouse models into human retinoblastoma. Cell Div (2008) 1.13
The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci (Landmark Ed) (2012) 1.12
Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood (2009) 1.11
CHD5, a brain-specific paralog of Mi2 chromatin remodeling enzymes, regulates expression of neuronal genes. PLoS One (2011) 1.11
Suppression of leukemia development caused by PTEN loss. Proc Natl Acad Sci U S A (2011) 1.10
The two faces of FBW7 in cancer drug resistance. Bioessays (2011) 1.08
Life in the fast lane: mammalian disease models in the genomics era. Cell (2012) 1.08
Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood (2008) 1.07
Somatic structural rearrangements in genetically engineered mouse mammary tumors. Genome Biol (2010) 1.06
Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice. Blood (2013) 1.06
NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia. J Exp Med (2010) 1.06
Minireview: animal models and mechanisms of ovarian cancer development. Endocrinology (2012) 1.04
The evolution of thymic lymphomas in p53 knockout mice. Genes Dev (2014) 1.04
Mouse models of prostate cancer. Prostate Cancer (2011) 1.04
RasGRP Ras guanine nucleotide exchange factors in cancer. Front Biol (Beijing) (2013) 1.04
Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood (2011) 1.03
Understanding telomere diseases through analysis of patient-derived iPS cells. Curr Opin Genet Dev (2013) 1.03
SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction. Cell Rep (2012) 1.03
Global genomic characterization of acute lymphoblastic leukemia. Semin Hematol (2009) 1.02
Ikaros and tumor suppression in acute lymphoblastic leukemia. Crit Rev Oncog (2011) 1.01
Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. PLoS One (2012) 1.00
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics (2004) 24.18
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature (1998) 10.58
TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell (1991) 10.06
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature (2000) 7.28
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
Array comparative genomic hybridization and its applications in cancer. Nat Genet (2005) 6.69
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol (1998) 6.38
p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell (1999) 5.93
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell (2003) 5.72
Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71
The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol (2004) 5.43
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat Genet (2001) 4.96
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35
Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell (2002) 4.29
A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell (1995) 4.02
High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Notch regulation of lymphocyte development and function. Nat Immunol (2004) 3.39
Activating Notch1 mutations in mouse models of T-ALL. Blood (2005) 3.08
Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell (2002) 3.06
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet (2004) 2.96
Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet (2001) 2.92
Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature (2003) 2.92
CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res (2005) 2.19
Abnormal rearrangement within the alpha/delta T-cell receptor locus in lymphomas from Atm-deficient mice. Blood (2000) 2.16
A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration. Genes Dev (1991) 2.14
ATM: genome stability, neuronal development, and cancer cross paths. Adv Cancer Res (2001) 2.05
Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle (2005) 1.88
Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer (2006) 1.36
Short telomeres and ataxia-telangiectasia mutated deficiency cooperatively increase telomere dysfunction and suppress tumorigenesis. Cancer Res (2003) 1.27
High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia (2006) 1.14
Array comparative genome hybridization for tumor classification and gene discovery in mouse models of malignant melanoma. Cancer Res (2003) 1.12
Telomere fusion to chromosome breaks reduces oncogenic translocations and tumour formation. Nat Cell Biol (2005) 1.11
Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias. Cancer Lett (2004) 1.09
Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol (2005) 1.07
Incomplete inhibition of the Rb tumor suppressor pathway in the context of inactivated p53 is sufficient for pancreatic islet tumorigenesis. Oncogene (2005) 1.02
Identification of alterations in DNA copy number in host stromal cells during tumor progression. Proc Natl Acad Sci U S A (2006) 0.99
The Notch1/c-Myc pathway in T cell leukemia. Cell Cycle (2007) 0.99
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
The cancer genome. Nature (2009) 23.13
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
A landscape of driver mutations in melanoma. Cell (2012) 12.61
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60